Chemed Corporation Reports Strong Q2 2026 Results: Shareholder Update and Guidance Revision
Key Highlights
- Material Earnings Growth: Chemed has revised its 2026 guidance upwards, with adjusted earnings per diluted share now expected to range from \$24.00 to \$24.75. The mid-point (\$24.38) marks a 17.8% increase over 2025’s adjusted EPS of \$21.55.
- Continued Share Repurchases: The company repurchased approximately 10.5% of its outstanding shares over the past 12 months, with \$139.8 million remaining under its current authorization as of June 30, 2026.
- Operational Outperformance: The guidance update is driven by VITAS’ materially improved performance and the impact of share repurchases.
- Tax and Share Count Assumptions: Guidance assumes an effective corporate tax rate of 24.5% and a diluted share count of 13.5 million shares.
- Conference Call: Chemed will host a webcast and teleconference on July 29, 2026, at 10 a.m. ET. Replay will be available on the investor relations section of the Chemed website.
Financial Performance Details
Income Statement Highlights
- Q2 2026 Service Revenues and Sales: \$673.3 million (up from \$584.0 million in Q2 2025).
- Net Income: \$67.7 million for Q2 2026; \$134.0 million for the first six months of 2026, compared to \$52.5 million and \$124.3 million respectively in 2025.
- Diluted EPS: Q2 2026: \$5.13 per share; Six months ended: \$9.97 per share. Adjusted diluted EPS: Q2 2026: \$6.06; Six months ended: \$11.71.
- EBITDA and Adjusted EBITDA: Consolidated Q2 2026 EBITDA: \$110.1 million; Adjusted EBITDA: \$121.8 million. Six months: EBITDA: \$216.3 million; Adjusted EBITDA: \$238.1 million.
Balance Sheet and Cash Flow
- Total Assets: \$1.58 billion as of June 30, 2026.
- Stockholders’ Equity: \$830.5 million (down from \$1.20 billion as of June 30, 2025, due to share repurchases).
- Cash and Cash Equivalents: \$40.2 million at period end (down from \$74.5 million at start of year).
- Long-Term Debt: \$140 million, reflecting new borrowings and repayment activity.
- Net Cash Used by Financing Activities: \$(141.3) million in the first six months of 2026, mainly due to share repurchases and debt repayments.
Shareholder-Relevant and Price-Sensitive Information
- Guidance Revision:
- Material increase in EPS guidance signals strong operational momentum and improved outlook for VITAS, Chemed’s hospice business.
- Guidance revisions may positively impact investor sentiment and share price.
- Share Repurchase Program:
- Chemed’s aggressive repurchase of 10.5% of shares outstanding enhances EPS and shareholder value.
- Remaining \$139.8 million authorization provides further support for share price.
- Margin Expansion:
- Adjusted EBITDA margin improvement reflects operational leverage and efficiency gains, particularly at VITAS.
- Tax Rate and Diluted Share Count:
- Lower share count and stable tax rate support higher EPS projections.
- Legal and Acquisition Expenses:
- One-time legal and acquisition charges are detailed, but after-tax impacts are not significant enough to offset positive core performance.
- Forward-Looking Statements:
- Chemed’s management notes risks tied to Medicare reimbursement rates, patient mix, and demand for Roto-Rooter services, which could affect future performance.
Conference Call Details
Chemed will host a conference call and webcast on July 29, 2026, at 10 a.m. ET to discuss quarterly results and business updates. Participation details are available via the investor relations section of Chemed’s website and a replay will be accessible two hours after the event.
Additional Operational and Segment Information
- Segment Results:
- VITAS continues to outperform, driving improved consolidated results.
- Roto-Rooter and Corporate segment results are detailed in the financial statements, with operating income and EBITDA breakdowns provided.
- Non-GAAP Metrics:
- Chemed uses EBITDA, Adjusted EBITDA, and Adjusted Diluted EPS to provide investors with a clearer view of operational performance, especially compared to peer companies.
- Reconciliations to GAAP net income are provided in the financial tables.
Conclusion
Chemed Corporation’s Q2 2026 financial results and guidance update reflect strong operational performance, significant EPS growth, and continued shareholder value creation through share repurchases. The revised guidance and margin improvements are price-sensitive and likely to positively affect share value. Investors should monitor future conference calls and regulatory risks, but the current outlook is robust and shareholder-friendly.
Disclaimer: This article is a summary of Chemed Corporation’s unaudited financial statements for Q2 2026 and related disclosures. It contains forward-looking statements based on management assumptions and market conditions as of the publication date. Actual results may differ materially due to risks such as regulatory changes, market conditions, and operational performance. Investors are advised to review official filings and consult with their financial advisors before making investment decisions.
